Otonomy, Inc. Logo
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy, Inc. Logo
Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update
October 29, 2019 16:05 ET | Otonomy, Inc.
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
June 12, 2019 08:00 ET | Otonomy, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 06, 2019 16:17 ET | Otonomy, Inc.
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial in Ménière’s disease on...
Otonomy, Inc. Logo
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
May 02, 2019 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
May 01, 2019 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy, Inc. Logo
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
April 29, 2019 16:05 ET | Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
April 11, 2019 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy to Participate in Two Upcoming Investor Conferences
March 05, 2019 07:30 ET | Otonomy, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...